Mankind Pharma Q2 FY27 Revenue surges 17.3% to ₹4,338 Cr; PAT up 37.7%
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 crore, up 17.3% YoY. EBITDA increased 27.2% to ₹1,175 crore, and PAT surged 37.7% to ₹716 crore. For H1 FY27, revenue grew 15.1% to ₹8,368 crore. Domestic business grew 14.8% and exports rose 32.7%. An earnings concall is scheduled for October 26, 2026.
The announcement details significant financial growth across key metrics (revenue, EBITDA, PAT) and business segments (domestic, exports), which is crucial information for investors and analysts, thus having a high impact.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for both the second quarter and the first half of FY27, indicating a positive financial performance.
Mankind Pharma Limited announced its financial results for the second quarter and half year ended September 30, 2026. The company reported a strong revenue growth of 17.3% year-on-year (YoY) to ₹4,338 crore for Q2 FY27. EBITDA saw a significant increase of 27.2% YoY to ₹1,175 crore, with EBITDA margins improving by 210 basis points to 27.1%. Profit After Tax (PAT) surged by 37.7% YoY to ₹716 crore, and PAT margin improved by 240 basis points to 16.5%.
For the half year ended September 30, 2026 (H1 FY27), revenue from operations grew by 15.1% YoY to ₹8,368 crore. EBITDA increased by 26.0% YoY to ₹2,235 crore, with EBITDA margins at 26.7%. PAT for H1 FY27 rose by 33.7% YoY to ₹1,290 crore, and PAT margin was 15.4%.
The domestic business, excluding Consumer Healthcare, grew by 14.8% YoY to ₹3,657 crore in Q2 FY27, driven by strong performance in both Mankind and BSV specialty businesses. Secondary sales growth was 15.7% against an industry growth of 14.2% (IPM), indicating an outperformance. The company highlighted robust growth in key chronic and acute brands. Exports grew significantly by 32.7% YoY to ₹681 crore in Q2 FY27.
The company has scheduled an earnings concall for October 26, 2026, from 5:00 pm to 6:00 pm IST to discuss the results.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.